Effective etrials for The Medicines Company
etrials Worldwide, a leading provider of eClinical software for the efficient collection, integration and review of data in the clinical trial process, announced that REPLACE-2, a clinical trial of The Medicines Company's Angiomax (bivalirudin), exclusively employed etrials' web-based data capture system, making it the largest 'paperless' clinical trial ever com-pleted by etrials.
All of the 233 clinical trial sites in the U.S., Canada, western Europe and Israel employed a real-time data entry system that was web-based and included etrials' QuickStudy Capture electronic data capture (EDC) technology and QuickStudy Touch services.
The data in REPLACE-2 was collected and entered rapidly, as the enrollment of more than 6,000 patients was completed in less than one year.
John Cline, ceo of etrials commented: 'The Medicines Company was a pioneering client for the REPLACE-2 study, which speaks to their innovative approach to clinical trial conduct and problem-solving. We were able to guide them through the process of turning an electronic technology into a solution that works on a scale we had never previously experienced for an acute care trial.
The Medicines Company recognised the importance of efficiency and solving the issues associated with paper in clinical trials and we are thrilled that they were able to meet or exceed their timeline goals through the use of etrials' technology and services.'